Wiki » History » Version 57
Jason Bobe, 03/02/2010 10:39 PM
changed my mind
1 | 36 | Jason Bobe | = Genotype + Environment = Trait Evidence (GET-E) Database = |
---|---|---|---|
2 | 1 | Jason Bobe | |
3 | 38 | Jason Bobe | The '''GET-E''' project was started by Abraham Rosenbaum, Joe Thakuria, Xiaodi Wu and Alexander Wait Zaranek to help the [http://personalgenomes.org Personal Genome Project], the clinical genetics community, and, the general public interpret individual genomes. The database is closely integrated with [wiki:Trait-o-matic]. |
4 | 1 | Jason Bobe | |
5 | You can find the PGP production server at: |
||
6 | * http://evidence.personalgenomes.org |
||
7 | |||
8 | A development sandbox can be found at: |
||
9 | * http://evidence-dev.personalgenomes.org |
||
10 | |||
11 | 37 | Jason Bobe | Many contributors helped make '''GET-E''' possible. You can find specific contributions at: |
12 | 1 | Jason Bobe | * http://evidence.personalgenomes.org/editors |
13 | |||
14 | 38 | Jason Bobe | Please help the project by editing the database, writing software tools that use the database (eg. Trait-o-matic/AETAS) or by making suggestions on the wiki! |
15 | 1 | Jason Bobe | |
16 | 28 | Jason Bobe | == Field Descriptions and Editing Guidelines == |
17 | 19 | Jason Bobe | === Short Summary === |
18 | * free text providing a one line summary of clinical action to be undertaken given this variant (possibly modified by known phenotypes). |
||
19 | |||
20 | 23 | Jason Bobe | === Variant Quality Data === |
21 | 1 | Jason Bobe | Each of these fields is a sliding scale of 0-5 where 0 represents no evidence and 5 strong evidence that the Impact is correct. Where the data is not entered the default is N/A. When Genetests and/or the literature correlate this variant with a number of phenotypes the impact should be reported for the most extreme condition |
22 | 35 | Jason Bobe | a. ''In silico'': One star for each consistent prediction and one star subtracted for conflicting results from: |
23 | 26 | Jason Bobe | i. evolutionary conservation (minimum of three species) |
24 | i. presence in active domain |
||
25 | 27 | Jason Bobe | i. SIFT |
26 | i. !PolyPhen |
||
27 | 44 | Jason Bobe | i. NBLOSUM >= 2 |
28 | 27 | Jason Bobe | i. GVGD |
29 | 23 | Jason Bobe | i. Other variants in this gene cause similar disease |
30 | i. etc... |
||
31 | a. ''In vitro'': One star for each experiment supporting the result, and penalize one star for conflicting results from: |
||
32 | i. enzyme extracts |
||
33 | i. cell lines |
||
34 | i. animal models |
||
35 | i. etc... |
||
36 | 50 | Jason Bobe | a. Case/Control: A combination of odds ratio and significance test (currently using Fisher's Exact Test). For protective alleles, use inverse OR = 1 / OR. Do not count related individuals, count probands -- ie. one per family |
37 | 40 | Jason Bobe | i. 0 stars if no higher ranking is allowed |
38 | 41 | Jason Bobe | i. 1 star if OR>1 and significance <= 0.1 |
39 | i. 2 stars if OR>=1.5 and significance <= 0.05 |
||
40 | 45 | Jason Bobe | i. 3 stars if OR>=2 and significance <= 0.025 |
41 | i. 4 stars if OR>=3 and significance <= 0.01 |
||
42 | i. 5 stars if OR>=5 and significance <= 0.0001 |
||
43 | 24 | Jason Bobe | a. Familial Disease Segregation |
44 | 25 | Jason Bobe | i. 0 stars for no segregation (LOD < -2) |
45 | 24 | Jason Bobe | i. 1 star if segregation exists in one family pedigree |
46 | i. 2 stars for segregation in more than one family with some conflicting information (e.g. asymptomatic carrier of young age or possibility of second causative mutation) |
||
47 | i. 3 stars for more than one family no conflicting information |
||
48 | i. 4 stars for LOD > 2 |
||
49 | 46 | Jason Bobe | i. 5 stars for LOD > 3 |
50 | 51 | Jason Bobe | a. Disease severity: downgraded according to disease penetrance (eg. Crohn's disease would be moderate or severe, but "increased susceptibility" is only increased the chances by ~.15% and so is called mild) |
51 | i. 0 stars for benign |
||
52 | 57 | Jason Bobe | i. 1 star for very mild effect (eg. increased susceptibility to Crohn's disease) |
53 | i. 2 stars for mild effect (eg. Alpha-1-antitrypsin deficiency) |
||
54 | 53 | Jason Bobe | i. 3 stars for moderate effect (eg. Cystineria) |
55 | i. 4 stars for severe effect: potentially lethal (eg. sickle-cell) |
||
56 | i. 5 stars for very severe effect: lethal or severe damage (eg. Bardet-Biedl, PKU) |
||
57 | 51 | Jason Bobe | a. Treatability: |
58 | i. 0 stars for no clinical evidence supporting intervention (eg. PAF acetylhydrolase deficiency) |
||
59 | i. 1 star for uncurable: treatment only to alleviate symptoms (eg. Bardet-Biedl) |
||
60 | i. 2 stars for potentially treatable: Treatment is in development or controversial |
||
61 | i. 3 stars for treatable: Well-established treatment reduces the amount of mortality/morbidity but does not eliminate it (eg. Sickle-cell disease) |
||
62 | i. 4 for very treatable: Well-established treatment greatly reduces the effect of the disease (eg. Cystinuria) |
||
63 | 54 | Jason Bobe | i. 5 stars for extremely treatable: Well-established treatment essentially eliminates the effect of the disease (eg. PKU) |
64 | 47 | Jason Bobe | |
65 | 19 | Jason Bobe | === Impact === |
66 | 32 | Jason Bobe | a. Pathogenic: Causative for disease. |
67 | a. Benign: No clinically significant phenotype. |
||
68 | 1 | Jason Bobe | a. Protective: Protective from disease. |
69 | a. Pharmacogenetic: Clinically significant phenotype in the presence of a pharmacological agent. |
||
70 | 43 | Jason Bobe | a. NR: Not reviewed. |
71 | 34 | Jason Bobe | |
72 | 56 | Jason Bobe | In addition to these impacts, qualifiers will be added according to the variant quality information (ie. the stars). |
73 | |||
74 | For pathogenic, pharmacogenetic, and protective variants: |
||
75 | a. (no qualifier given): at least 4 stars in one of the human evidence categories (case/control or familial), at least 4 stars in one of the clinical categories (severity or treatability), and at least 14 stars total. |
||
76 | a. "likely": at least 3 stars in one of the human evidence categories, at least 3 stars in one of the clinical categories, and at least 10 stars total. |
||
77 | a. "uncertain": all the rest. |
||
78 | |||
79 | For benign: |
||
80 | a. (no qualifier given): at least 4 stars in one of the human evidence categories, and at least 10 stars total. |
||
81 | a. "likely": at least 3 stars in one of the human evidence categories, and at least 6 stars total. |
||
82 | a. "uncertain": all the rest. |
||
83 | 39 | Jason Bobe | |
84 | When Genetests and/or the literature give multiple phenotypes for a variant, the impact should be reported for the most extreme condition and annotated as such in the ''short summary''. In the future we hope to list different phenotypes separately. |
||
85 | 19 | Jason Bobe | |
86 | === Inheritance Pattern === |
||
87 | a. Dominant |
||
88 | a. Recessive |
||
89 | a. Other: A defined form of inheritance that is neither dominant or recessive (e.g. modifier, co-dominant, incomplete penetrance). These variants will get prioritized due to their potential phenotypic affect should the additional factors be present. |
||
90 | a. Undefined: Undefined in the literature. |
||
91 | a. Unknown: The default value for all variants and all variants without literature. |
||
92 | |||
93 | === Summary of published research, and additional commentary === |
||
94 | 22 | Jason Bobe | * Free text providing a comprehensive review of the variant including youngest age of onset, oldest age of onset and oldest asymptomatic individual. |
95 | 1 | Jason Bobe | |
96 | 21 | Jason Bobe | === Allele Frequency === |
97 | 22 | Jason Bobe | * Automatically generated frequencies for the !HapMap Project, 1000 Genomes Project and the weighted average of the two. Sub-population frequencies and homozygous/heterozygous break-downs are currently not shown. |
98 | 21 | Jason Bobe | |
99 | === Publications === |
||
100 | |||
101 | * User-entered publications and user entered synopses of the relevant details from the publication. A short summary is also entered for each paper (as above). |
||
102 | |||
103 | === Genomes === |
||
104 | |||
105 | * Automatically generated list of all genomes from Trait-o-matic in which this variant is seen. Additionally, specific actions taken by each individual harboring the variant can be reported. |
||
106 | |||
107 | === Other External References === |
||
108 | These are automatically generated by web "robots": |
||
109 | 13 | Jason Bobe | a. dbSNP: The link to the dbSNP entry for this nucleotide position (for this nucleotide change?) |
110 | 12 | Jason Bobe | a. Genetests: Link to all clinical laboratories performing diagnostic tests on this gene and the list of diseases that the labs are looking for. |
111 | a. Web Search Results: A web search for this exact variant using the Yahoo search engine |
||
112 | 21 | Jason Bobe | |
113 | === Edit History === |
||
114 | * Automatically generated history of all page edits with the contributor's name. |
||
115 | 20 | Jason Bobe | |
116 | == To Do == |
||
117 | * [wiki:GET-Evidence/23andWe] |
||
118 | 3 | Jason Bobe | |
119 | 1 | Jason Bobe | == Suggestions == |
120 | |||
121 | * your suggestion here. |